1,558
Views
0
CrossRef citations to date
0
Altmetric
Perspective

In memoriam: Jefferson Foote

, , , , &
Article: 1870059 | Received 13 Dec 2020, Accepted 23 Dec 2020, Published online: 12 Jan 2021

References

  • Jones PT, Dear PH, Foote J, Neuberger MS, Winter G. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature. 1986;321(6069):522–3. PM:3713831. doi:10.1038/321522a0.
  • Foote J, Winter G. Antibody framework residues affecting the conformation of the hypervariable loops. J Mol Biol. 1992;224(2):487–99. doi:10.1016/0022-2836(92)91010-M.
  • Riechmann L, Clark M, Waldmann H, Winter G. Reshaping human antibodies for therapy. Nature. 1988;332(6162):323–7. PM:3127726. doi:10.1038/332323a0.
  • Foote J, Milstein C. Kinetic maturation of an immune response. Nature. 1991;352(6335):530–32. doi:10.1038/352530a0.
  • Foote J, Milstein C. Conformational isomerism and the diversity of antibodies. Proc Natl Acad Sci U S A. 1994;91(22):10370–4. PMCID: PMCPMC45021. doi:10.1073/pnas.91.22.10370.
  • Holmes MA, Buss TN, Foote J. Structural effects of framework mutations on a humanized anti-lysozyme antibody. J Immunol. 2001;167(1):296–301. doi:10.4049/jimmunol.167.1.296.
  • Tan P, Mitchell DA, Buss TN, Holmes MA, Anasetti C, Foote J. “Superhumanized” antibodies: reduction of immunogenic potential by complementarity-determining region grafting with human germline sequences: application to an anti-CD28. J Immunol. 2002;169(2):1119–25. doi:10.4049/jimmunol.169.2.1119.
  • O’Hear CE, Foote J. Antibody buffering of a ligand in vivo. Proc Natl Acad Sci U S A. 2005;102(1):40–4. PM:15615858. doi:10.1073/pnas.0405797102.